Skip to content
Screener

LivaNova LIVN Cardiopulmonary — Foreign currency adjustments

Other segment segments

Neuromodulation
$0—

Similar metrics at other companies

Fidelity National Information Services logo
FISBanking Solutions — Foreign currency adjustments
-$46M-356%
Fidelity National Information Services logo
FISCapital Market Solutions — Foreign currency adjustments
-$23M-156%
Fidelity National Information Services logo
FISCorporate and Other — Foreign currency adjustments
$0—
Wintrust Financial logo
WTFCCommunity Banking — Foreign Currency Adjustments
-$11.33M—
Wintrust Financial logo
WTFCSpecialty finance — Foreign Currency Adjustments
$10.89M+799%
Wintrust Financial logo
WTFCWealth management — Foreign Currency Adjustments
$0—

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemCardiopulmonaryNeuromodulationTotal
December 31, 2025$394,086$398,754$792,840
Foreign currency adjustments(13,696)—(13,696)
June 30, 2026$380,390$398,754$779,144

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's cardiopulmonary — foreign currency adjustments?
LivaNova (LIVN) reported cardiopulmonary — foreign currency adjustments of -$6.45M in Q2 2026.
How has LivaNova's cardiopulmonary — foreign currency adjustments changed year-over-year?
LivaNova's cardiopulmonary — foreign currency adjustments decreased by 120.5% year-over-year, from $31.45M to -$6.45M.
What does cardiopulmonary — foreign currency adjustments mean?
Reflects the impact of exchange rate fluctuations on the cardiopulmonary segment's financial results when translating international operations into the reporting currency. This metric helps isolate the effect of currency volatility from underlying operational performance.

Ask your AI about LivaNova's cardiopulmonary — foreign currency adjustments.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude